Drug intelligence / Profile preview

4D9

Development stage: Preclinical
Lead developer: C.H.
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intraperitoneal

Overview

4D9 is a TREM2 agonistic antibody developed by C.H. It has been shown to inhibit necrotic core formation in experimental atherosclerosis by activating the Triggering Receptor Expressed on Myeloid cells 2 (TREM2), which plays a crucial role in macrophage functions related to lipid uptake, survival, and efferocytosis. This activation helps to limit plaque necrosis and promote the stabilization of atherosclerotic lesions.

Targets

TREM2 (Triggering receptor expressed on myeloid cells 2)

Beyond the preview

Go deeper on 4D9.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4D9.

Explore the full profile